Baxter International focuses on dialysis and hospital portfolio, shares on NYSE under analyst watch

Baxter International opens the week with its diversified medical technology portfolio in focus. The S&P 500 healthcare supplier remains on NYSE investors' radar as consensus expectations and upcoming events shape sentiment around the shares.

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-23, 16:38.

Baxter International Inc. (US0673431090) sits in the S&P 500 healthcare cohort with a broad hospital and renal-care portfolio. The NYSE-listed company remains closely tracked by Wall Street consensus estimates and sector comparisons that frame expectations for the shares according to current analyst data.

Consensus view on Baxter

Analyst compilations on MarketScreener show Baxter covered by a double-digit number of research houses, with most ratings clustered between Hold and Buy on a 12-month view, alongside published price targets denominated in US dollars. That cross-section reflects cautious optimism in the US medtech peer group around Baxter compared with names like Medtronic or Becton Dickinson in similar hospital-supply niches.

Consensus figures collected by MarketScreener and similar platforms indicate that analysts expect Baxter to deliver single-digit percentage revenue growth over the coming years, with margin improvement tied to portfolio optimization efforts and cost programs across its renal and hospital products. The company’s latest annual revenue base in the multi-billion dollar range is used as the reference point for those projections.

How Baxter fits the sector

Within the wider S&P 500 healthcare space, Baxter competes with diversified suppliers such as Medtronic, Becton Dickinson and ICU Medical for hospital capital spending, consumables and digital solutions budgets. The company targets acute care, operating rooms and chronic kidney disease treatment, positioning itself as a systems partner for clinics rather than a pure single-product vendor.

US hospital and procedure volumes, reimbursement frameworks for dialysis and competition from generic device makers shape the revenue trajectory for Baxter’s consumables and equipment lines. Investors also compare Baxter’s balance sheet metrics and free cash flow to those of other large-cap medtech names when assessing valuation multiples on the NYSE.

What Baxter sells in hospitals

Baxter generates a significant share of its revenue with products for renal therapy and hospital care, including hemodialysis machines, peritoneal dialysis solutions and infusion systems used in acute and intensive-care settings. The portfolio also spans IV fluids, injectable drugs, nutrition products and related disposables designed for everyday hospital workflows worldwide.

Where the shares trade today

The Baxter International shares (US0673431090) trade on the NYSE in US dollars; the latest verifiable quote places the stock in the mid-double-digit price range as of 2026-06-23, 16:30.

Key data on the Baxter International shares

• Company: Baxter International Inc.
• ISIN: US0673431090
• WKN: 853815
• Ticker: BAX
• Trading venue: NYSE
• Price (as of 2026-06-23, 16:30): mid double-digit range USD
• Market cap: tens of billions USD (as of 2026-06-23)
• Sector / industry: Health Care Equipment & Supplies
• Index membership: S&P 500
• Next earnings date: not officially scheduled

This article is for informational purposes only and does not constitute investment advice or a solicitation to buy or sell any securities.